Cargando…
Role of atezolizumab therapy combined with platinum-based chemotherapy in untreated metastatic urothelial carcinoma – The new landscapes (IMvigor130 trial)
Autor principal: | Misra, Ankit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388348/ https://www.ncbi.nlm.nih.gov/pubmed/34465965 http://dx.doi.org/10.4103/iju.IJU_576_20 |
Ejemplares similares
-
POUT trial: Perioperative chemotherapy in upper tract urothelial carcinoma – A standard of care?
por: Ranjan, Satish Kumar
Publicado: (2020) -
Nectin-4 inhibitors: An ace up our sleeve against advanced urothelial carcinoma
por: Kumaraswamy, Santosh
Publicado: (2021) -
Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
por: Mishra, Ankit
Publicado: (2020) -
Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma?
por: Kumar, Naveen
Publicado: (2021) -
Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)